ProtoKinetix,
Incorporated (OTC: PKTX) (www.protokinetix.com)
(“ProtoKinetix” or the “Company”) is pleased to announce that it has
completed the acquisition of certain patents and all rights associated
therewith (the “Patents”) from Institut National des Sciences Appliquées
de Rouen (“INSA”) pursuant to an Assignment of Patents and Patent
Application (the “Patent Assignment”) entered into on or about January
5, 2015.
ProtoKinetix made payment of 25,000 Euros to INSA for all of the Patents
and rights associated therewith, for the “Gem difluorinated
C-glycopeptides, their preparation and their use for the preservation of
biological materials and/or in cryosurgery” family of patents, which
includes issued patents in Canada (Patent No. CA2,558,801), England,
France, and Germany (Patent No. EP1,817,329) and the United-States
(Patent No. US8,394,362). These Patents secure, amongst other things,
key intellectual property rights to the Company’s AAGP™ lead compound.
By securing these Patents, the Company is in a better position to move
forward with its operations. “We are pleased to secure the rights to
these Patents as we can now license the rights to other companies to
develop different applications of the AAGP™ lead compound,” said
Clarence E. Smith, President and Chief Executive Officer.
About ProtoKinetix
ProtoKinetix, Inc. is a molecular biotechnology company that has
developed and patented a family of hyper stable, potent glycopeptides
(AAGP™) that dramatically enhance therapeutic results and reduce the
cost of stem cell medicine. Due to the anti-inflammatory effect of AAGP™
molecules, the Company is currently targeting the direct treatment of
diseases that have a major inflammatory component.
Cautionary Statement Regarding Forward-Looking Information
Except for statements of historical fact, this news release contains
certain “forward-looking information” within the meaning of applicable
securities law, including statements regarding the Company's intention
to license the Patent rights to third parties and the potential
treatments for which the Company's AAGPTM may
be applied. Forward-looking information is frequently characterized by
words such as “plan”, “expect”, “project”, “intend”, “believe”,
“anticipate”, “estimate” and other similar words, or statements that
certain events or conditions “may” or “will” occur. Forward-looking
statements are based on the opinions and estimates of management at the
date the statements are made, and are subject to a variety of risks and
uncertainties and other factors that could cause actual events or
results to differ materially from those anticipated in the
forward-looking statements. The Company undertakes no obligation
to update forward-looking information if circumstances or management’s
estimates or opinions should change except as required by law. The
reader is cautioned not to place undue reliance on forward-looking
statements. More detailed information about potential factors
that could affect financial results is included in the documents filed
by the Company from time to time with the United States Securities
Commission and with securities regulatory authorities in Canadian on
SEDAR.
The Private Securities Litigation Reform Act of 1995 provides a “safe
harbor” for forward-looking statements. Some information included in
this press release contains statements that are forward-looking. Such
forward-looking information involves significant risks and uncertainties
that could affect anticipated results in the future and, accordingly,
these results may differ materially from those expressed in any
forward-looking statements made by or on behalf of the Company. For a
description of additional risks and uncertainties, please refer to the
Company’s filings with the Securities and Exchange Commission.
Clarence E. Smith – President and CEO
Copyright Business Wire 2015